<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529048</url>
  </required_header>
  <id_info>
    <org_study_id>INK-GLUKOSE1</org_study_id>
    <nct_id>NCT00529048</nct_id>
  </id_info>
  <brief_title>Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes</brief_title>
  <official_title>Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes Using Increasing Amounts of Oral Glucose Challenges</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Forskningsrådet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetesforeningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with T2DM lac a sufficient incretin response after oral glucose intake. It has only
      been tested using 50g of glucose. We don't know if patients with T2DM are capable of
      regulating the incretin effect like healthy people in responds to different amounts of
      glucose intake.

      The aim of the present study is to quantify the incretin effect in healthy subjects and in
      patients with T2DM during increasing amounts of oral glucose challenges. The proposed studies
      will answer important questions on the mechanisms underlying T2DM and be of importance in
      relation to future preventive- and treatment strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impaired incretin effect in patients with type 2 diabetes mellitus (T2DM) has previously
      only been evaluated using a glucose load of 50 g, and it is uncertain whether patients with
      T2DM are capable of regulating their incretin effect equivalent to healthy subjects.
      Furthermore, it is of great interest to quantify the secretion of GIP and GLP-1 during
      increasing glucose loads in both patients with T2DM and in healthy subjects in order to
      evaluate whether an increased secretion of one or both of the two incretin hormones
      contributes to the regulation of the incretin effect.

      The aim of the present study is to quantify the incretin effect in healthy subjects and in
      patients with T2DM during increasing amounts of oral glucose challenges and corresponding
      isoglycemic iv glucose challenges. The proposed studies will answer important questions on
      the pathophysiology underlying T2DM and be of importance in relation to future preventive-
      and treatment strategies.

      Eight patients with T2DM and 8 matched healthy subjects will be evaluated with oral glucose
      tolerance tests (OGTT) using increasing glucose loads (25, 50 and 100 g glucose) and
      isoglycemic iv glucose tolerance tests imitating the glucose concentrations as obtained
      during the oral glucose loads. The results will describe the regulation of the incretin
      effect in patients with T2DM and, thereby, contribute to the clarification of the
      pathophysiology of the postprandial hyperglycemia characterizing these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progress in Incretin effect in patients with T2DM compared with healthy subjects</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GIP and GLP-1 responscurvs</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Incretin Effect</condition>
  <arm_group>
    <arm_group_label>T2DM</arm_group_label>
    <description>T2DM patients (WHO-criteria)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTRL</arm_group_label>
    <description>Healthy control subjects matched individually to the cases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test</intervention_name>
    <description>The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.</description>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>CTRL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isoglycemic clamp</intervention_name>
    <description>I.v. glucose infusion initiating the glucose responds curves from the OGTT</description>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>CTRL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gastric emptying rate</intervention_name>
    <description>Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve</description>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>CTRL</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      p-Glucose p-Glucagon p-insulin p-c-pep. p-GLP-1 p-GIP Buffy coat s-paracetamol
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The Patients (Cases) will be recruted from the diabetes clinic at Depatment of
        Endocrinology at Herlev Hospital

        The control subjects will be recruted through the lokal papers, and individualy matched by
        age, sex and BMI to a patient befor enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Cases

          -  Caucasians with T2DM according to WHO's criteria

          -  Normal Hemoglobin

          -  Agree to participate (orally and in writing)

          -  HbA1c: 6.5-9 %

          -  BMI: 23-35 kg/m2

        Exclusion Criteria:Cases

          -  Liver disease (ALAT &gt; 2 x normal level)

          -  Diabetic nephropathy (s-creatinin &gt; 130 µM or albuminuria)

          -  Diabetic neuropathy (anamnestic)

          -  Proliferative diabetic retinopathy (anamnestic)

          -  Medical treatment witch cannot be stopped for 12 hours

          -  Pregnancy or breastfeed

          -  Treatment with Insulin or glitazones

        Inclusion Criteria: Control group

          -  Caucasians

          -  Normal oral glucose tolerance according to WHO's criteria

          -  Normal Hemoglobin

          -  Agree to participate (orally and in writing)

          -  BMI: 23-35 kg/m2

        Exclusion Criteria: Control group

          -  Liver disease (ALAT &gt; 2 x normal level)

          -  Impaired function of the kidney (s-creatinin &gt; 130 µM or albuminuria)

          -  Directly related til to someone suffering from diabetes mellitus

          -  Medical treatment witch cannot be stopped for 12 hours

          -  Pregnancy or breastfeed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Villsbøll, MD.DMSc.</last_name>
    <role>Study Chair</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip K Knop, MD.Phd.</last_name>
    <role>Study Director</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endokrinologisk afd. J, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Region Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Kolligs F, Fehmann HC, Göke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes. 1995 Jan;44(1):16-9.</citation>
    <PMID>7813808</PMID>
  </reference>
  <reference>
    <citation>Tseng CC, Zhang XY, Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol. 1999 Jun;276(6 Pt 1):E1049-54.</citation>
    <PMID>10362617</PMID>
  </reference>
  <reference>
    <citation>Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest. 1995 Jan;95(1):417-21.</citation>
    <PMID>7814643</PMID>
  </reference>
  <reference>
    <citation>Habener JF. The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am. 1993 Dec;22(4):775-94. Review.</citation>
    <PMID>8125072</PMID>
  </reference>
  <reference>
    <citation>Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999 Jan;48(1):86-93.</citation>
    <PMID>9892226</PMID>
  </reference>
  <reference>
    <citation>Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 2003 Feb;46(2):222-30. Epub 2003 Feb 12.</citation>
    <PMID>12627321</PMID>
  </reference>
  <reference>
    <citation>Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14843-7.</citation>
    <PMID>10611300</PMID>
  </reference>
  <reference>
    <citation>Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996 Nov;2(11):1254-8.</citation>
    <PMID>8898756</PMID>
  </reference>
  <reference>
    <citation>Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986 Jan;29(1):46-52.</citation>
    <PMID>3514343</PMID>
  </reference>
  <reference>
    <citation>Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.</citation>
    <PMID>12189441</PMID>
  </reference>
  <reference>
    <citation>Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003 Feb;52(2):380-6.</citation>
    <PMID>12540611</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986 Aug;63(2):492-8.</citation>
    <PMID>3522621</PMID>
  </reference>
  <reference>
    <citation>Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003 Jul 15;114(2-3):115-21.</citation>
    <PMID>12832099</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>October 19, 2009</last_update_submitted>
  <last_update_submitted_qc>October 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jonatan Bagger</name_title>
    <organization>University of Copehagen</organization>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Incretin effect</keyword>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>Gastric Inhibitory Polypeptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Incretins</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 13, 2011</submitted>
    <returned>June 14, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

